Eli Lilly's Trulicity shows promise in delivering efficacy in type 2 diabetes
Two investigational doses of Lilly's dulaglutide - 4.5 mg and 3.0 mg -, as well as Trulicity 1.5 mg, provided significantly better blood sugar control with weight benefits compared to placebo in adults with type 2 diabetes. Trulicity is Eli Lilly's once-weekly, injectable glucagon-like peptide-1 receptor agonist approved to improve blood sugar in adults with type 2 diabetes. At the study's primary endpoint of 18 weeks, the investigational dulaglutide 4.5 mg and 3.0 mg doses, as well as the currently approved Trulicity 1.5 mg dose, led to superior A1C reductions from baseline in people with type 2 diabetes who remained on treatment throughout the study compared to placebo. The investigational dulaglutide doses also led to significant weight loss compared to placebo, as did Trulicity 1.5 mg. The most commonly reported side effects were gastrointestinal-related and consistent with the GLP-1 RA class. These events included nausea. Trulicity 1.5 mg had a similar side effect profile to previous studies. No participants in any of the treatment groups experienced severe hypoglycemia. The safety and efficacy of the dulaglutide investigational doses are being studied further in a large, Phase 3 clinical trial, AWARD-11. The study is expected to complete in 2019.